## Special Issue

# Early Diagnosis and Diagnostic Delay in Oral Cancer

## Message from the Guest Editor

Oral and oropharyngeal cancer is the sixth most common malignancy, with an estimated annual mortality from oral cancer of 177,384 people in 2018. Five-year survival rates for this neoplasm have stayed below 50% during the past few decades despite the undeniable diagnostic and therapeutic contributions made by the scientific community to improve this situation. Oral cancer is mainly diagnosed at advanced stages, a fact that influences survival, as it has been reported that if these tumors were to be treated at earlier stages, survival rates would increase by up to 80%.

Thus, strategies to achieve early diagnoses and treatment may have a significant impact not only on patient survival but also on the morbidity and economic burden of the disease.

## **Guest Editor**

Dr. Pablo Varela-Centelles

Department of Surgery and Medical-Surgical Specialities, School of Medicine and Dentistry, University of Santiago de Compostela, 15705 Santiago de Compostela, Spain

#### Deadline for manuscript submissions

closed (30 June 2021)



## Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/53888

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

#### **Editor-in-Chief**

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

### **Author Benefits**

## **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

